AIO-STO-0417- MOONLIGHT Patients with Her2 negative, previously untreated metastatic esophagogastric adenocarcinoma will be treated with modified FOLFOX or with modified FOLFOX plus Nivolumab and Ipilimumab. The groups will be compared for time until progression of the disease (primary endpoint) as well as for response to the treatment, overall survival, safety/tolerability of the treatment and quality of life (Aktiv)
Amgen 20210098 - FORTITUDE-102 Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (Aktiv)
CA209-649 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (Aktiv)
COMPETE Eine prospektive, randomisierte, kontrollierte, offene, multizentrische Phase III Studie zur Beurteilung der Wirksamkeit und Sicherheit der Peptid-Rezeptor-Radionuklid-Therapie (PRRT) mit 177Lutetium-Edotreotid im Vergleich zur gezielten molekularen Therapie mit Everolimus bei Patienten mit inoperablen, progressiven, Somatostatin-Rezeptor positiven (SSTR +), neuroendokrinen Tumoren des Magen-Darm Trakts oder pankreatischen Ursprungs (GEP-NET) (Aktiv)
DANTE / FLOT8 Phase-II-Studie zu Atezolizumab + FLOT vs FLOT allein bei Magenkrebs und Adenokarzinom des ösophagogastralen Übergangs (Aktiv)
ESOPEC Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus (Aktiv)
MEMORI Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction (Aktiv)
MK7902-015 Eine randomisierte Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit von Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapie im Vergleich zur Standardtherapie als Erstlinienintervention bei Teilnehmern mit fortgeschrittenem/metastasierendem gastroösophagealem Adenokarzinom (LEAP-015) (Aktiv)
SAGA/AIO-STO-0123 A Phase Ib/II Single-arm, Multicenter Study of Sacituzumab-govitecan, a TROP-2 Targeting Antibody Linked With SN38, for Patients With Metastatic Esophagogastric Adenocarcinoma (Aktiv)
SPOT Pilot study of dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus (Aktiv)
Zweitlinie oder später
AMG 199 Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer (Aktiv)
AMG910 Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (Aktiv)
CVPM087A2101 Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (Aktiv)
Destiny 03 Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03) (Aktiv)
EORTC Vestige Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE) (Aktiv)
FLOT 9 HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) (Aktiv)
I4T-NS-O038 - RE-ExPEL Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction (Aktiv)
INTEGRATE IIb Studie To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC. (Aktiv)
MK-3475_06B-04 A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B (Aktiv)
Novartis CFKA115A12101 A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Tislelizumab in Patients With Select Advanced Cancers (Aktiv)
RACE Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ (Aktiv)
RAMIRIS_AIO STO 0415 Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Gastric Cancer (Aktiv)